⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576330 | 1.00 | — | — | |
| Resorcinol SCHEMBL326229 | 0.77 | CA12 (1.00) | — | |
| SCHEMBL2186969 | 0.77 | — | — | |
| Resorcinol SCHEMBL15515 | 0.77 | — | — | |
| Resorcinol SCHEMBL971994 | 0.74 | — | — | |
| Resorcinol SCHEMBL20577903 | 0.74 | — | — | |
| Resorcinol SCHEMBL563023 | 0.74 | CA12 (0.92) | — | |
| Resorcinol SCHEMBL8442393 | 0.74 | — | — | |
| Resorcinol SCHEMBL8829963 | 0.74 | — | — | |
| Resorcinol SCHEMBL11679916 | 0.74 | CA12 (0.92) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6117873-A | CAN BE USED FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS WHICH RESPOND TO BLOCKAGE OF EXCITATORY AMINO ACID RECEPTORS | NOVARTIS AG (CH) | 2000-09-12 | — | — | US | claimed |
| EP-0934326-A1 | SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS | Novartis AG (CH) | 1999-08-11 | — | — | EP | claimed |
| WO-1998017672-A1 | SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | claimed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-6117873-A | CAN BE USED FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS WHICH RESPOND TO BLOCKAGE OF EXCITATORY AMINO ACID RECEPTORS | NOVARTIS AG (CH) | 2000-09-12 | — | — | US | disclosed |
| EP-0934326-A1 | SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS | Novartis AG (CH) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017672-A1 | SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | disclosed |